Skip to main content
ENTYVIO 108 mg/.68mL injection, solution by Takeda Pharmaceuticals America, Inc.
ENTYVIO, 108 mg/.68mL, injection, solution Drug class: Integrin Receptor Antagonist. Available on prescription only. Listed by Takeda Pharmaceuticals America, Inc..
Prescription only

ENTYVIO

vedolizumab

Listed by Takeda Pharmaceuticals America, Inc.

Strength
108 mg/.68mL
Form
Injection, Solution
Route
Subcutaneous
Class
Integrin Receptor Antagonist

What it contains

  • Vedolizumab 108 mg/.68mL

FDA record

Dosage form Injection, Solution
Route Subcutaneous
Drug class Integrin Receptor Antagonist
Approval route BLA — biologic licence
NDC code 64764-107
FDA application BLA761133
RxNorm concept 1538137
Package sizes listed 1
Marketed since September 2023

Other products containing Vedolizumab

See all

Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.

Entyvio

vedolizumab

Strength
300 mg/5mL
Form
Injection, Powder, Lyophilized, For Solution
Class
Integrin Receptor Antagonist
Rx only

Takeda Pharmaceuticals America, Inc.

Not stocked by us — reference only

ENTYVIO Pen

vedolizumab

Strength
108 mg/.68mL
Form
Injection, Solution
Class
Integrin Receptor Antagonist
Rx only

Takeda Pharmaceuticals America, Inc.

Not stocked by us — reference only

Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.